858 related articles for article (PubMed ID: 23539443)
41. IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft.
Martins-Neves SR; Paiva-Oliveira DI; Fontes-Ribeiro C; Bovée JVMG; Cleton-Jansen AM; Gomes CMF
Cancer Lett; 2018 Feb; 414():1-15. PubMed ID: 29126913
[TBL] [Abstract][Full Text] [Related]
42. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
Croy HE; Fuller CN; Giannotti J; Robinson P; Foley AVA; Yamulla RJ; Cosgriff S; Greaves BD; von Kleeck RA; An HH; Powers CM; Tran JK; Tocker AM; Jacob KD; Davis BK; Roberts DM
J Biol Chem; 2016 Jun; 291(24):12747-12760. PubMed ID: 27068743
[TBL] [Abstract][Full Text] [Related]
43. C644-0303, a small-molecule inhibitor of the Wnt/β-catenin pathway, suppresses colorectal cancer growth.
Yan Y; Zhang Y; Li M; Zhang Y; Zhang X; Zhang X; Xu Y; Wei W; Wang J; Xu X; Song Q; Zhao C
Cancer Sci; 2021 Nov; 112(11):4722-4735. PubMed ID: 34431598
[TBL] [Abstract][Full Text] [Related]
44. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
[TBL] [Abstract][Full Text] [Related]
45. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T; Rabkin SD; Martuza RL
Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
[TBL] [Abstract][Full Text] [Related]
46. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging.
Yeh CT; Rao YK; Ye M; Wu WS; Chang TC; Wang LS; Wu CH; Wu AT; Tzeng YM
Toxicol Appl Pharmacol; 2012 May; 261(1):31-41. PubMed ID: 22465936
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines.
Wang W; Liu P; Lavrijsen M; Li S; Zhang R; Li S; van de Geer WS; van de Werken HJG; Peppelenbosch MP; Smits R
Sci Rep; 2021 Apr; 11(1):7470. PubMed ID: 33811251
[TBL] [Abstract][Full Text] [Related]
48. Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers.
Song S; Christova T; Perusini S; Alizadeh S; Bao RY; Miller BW; Hurren R; Jitkova Y; Gronda M; Isaac M; Joseph B; Subramaniam R; Aman A; Chau A; Hogge DE; Weir SJ; Kasper J; Schimmer AD; Al-awar R; Wrana JL; Attisano L
Cancer Res; 2011 Dec; 71(24):7628-39. PubMed ID: 22009536
[TBL] [Abstract][Full Text] [Related]
49. A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.
Menon M; Elliott R; Bowers L; Balan N; Rafiq R; Costa-Cabral S; Munkonge F; Trinidade I; Porter R; Campbell AD; Johnson ER; Esdar C; Buchstaller HP; Leuthner B; Rohdich F; Schneider R; Sansom O; Wienke D; Ashworth A; Lord CJ
Sci Rep; 2019 Jan; 9(1):201. PubMed ID: 30655555
[TBL] [Abstract][Full Text] [Related]
50. Disruption of Wnt/β-Catenin Signaling and Telomeric Shortening Are Inextricable Consequences of Tankyrase Inhibition in Human Cells.
Kulak O; Chen H; Holohan B; Wu X; He H; Borek D; Otwinowski Z; Yamaguchi K; Garofalo LA; Ma Z; Wright W; Chen C; Shay JW; Zhang X; Lum L
Mol Cell Biol; 2015 Jul; 35(14):2425-35. PubMed ID: 25939383
[TBL] [Abstract][Full Text] [Related]
51. KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer.
Cho YH; Cha PH; Kaduwal S; Park JC; Lee SK; Yoon JS; Shin W; Kim H; Ro EJ; Koo KH; Park KS; Han G; Choi KY
Oncotarget; 2016 Dec; 7(49):81727-81740. PubMed ID: 27835580
[TBL] [Abstract][Full Text] [Related]
52. AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
Scarborough HA; Helfrich BA; Casás-Selves M; Schuller AG; Grosskurth SE; Kim J; Tan AC; Chan DC; Zhang Z; Zaberezhnyy V; Bunn PA; DeGregori J
Clin Cancer Res; 2017 Mar; 23(6):1531-1541. PubMed ID: 27663586
[No Abstract] [Full Text] [Related]
53. Pinworm and TNKS inhibitors, an eccentric duo to derail the oncogenic WNT pathway.
Ouelaa-Benslama R; Emami S
Clin Res Hepatol Gastroenterol; 2011 Sep; 35(8-9):534-8. PubMed ID: 21782548
[TBL] [Abstract][Full Text] [Related]
54. WIKI4, a novel inhibitor of tankyrase and Wnt/ß-catenin signaling.
James RG; Davidson KC; Bosch KA; Biechele TL; Robin NC; Taylor RJ; Major MB; Camp ND; Fowler K; Martins TJ; Moon RT
PLoS One; 2012; 7(12):e50457. PubMed ID: 23227175
[TBL] [Abstract][Full Text] [Related]
55. Tankyrase Regulates Neurite Outgrowth through Poly(ADP-ribosyl)ation-Dependent Activation of β-Catenin Signaling.
Mashimo M; Kita M; Uno A; Nii M; Ishihara M; Honda T; Gotoh-Kinoshita Y; Nomura A; Nakamura H; Murayama T; Kizu R; Fujii T
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269974
[TBL] [Abstract][Full Text] [Related]
56. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
57. LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors.
de la Roche M; Ibrahim AE; Mieszczanek J; Bienz M
Cancer Res; 2014 Mar; 74(5):1495-505. PubMed ID: 24419084
[TBL] [Abstract][Full Text] [Related]
58. The Synthetic Small Molecule FL3 Combats Intestinal Tumorigenesis via Axin1-Mediated Inhibition of Wnt/β-Catenin Signaling.
Jackson DN; Alula KM; Delgado-Deida Y; Tabti R; Turner K; Wang X; Venuprasad K; Souza RF; Désaubry L; Theiss AL
Cancer Res; 2020 Sep; 80(17):3519-3529. PubMed ID: 32665357
[TBL] [Abstract][Full Text] [Related]
59. Discovery of a Novel Triazolopyridine Derivative as a Tankyrase Inhibitor.
Ryu H; Nam KY; Kim HJ; Song JY; Hwang SG; Kim JS; Kim J; Ahn J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298950
[TBL] [Abstract][Full Text] [Related]
60. Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.
Zagani R; Hamzaoui N; Cacheux W; de Reyniès A; Terris B; Chaussade S; Romagnolo B; Perret C; Lamarque D
Gastroenterology; 2009 Oct; 137(4):1358-66.e1-3. PubMed ID: 19549529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
